

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

MEDICIS PHARMACEUTICAL CORP
Form 8-K
July 15, 2004

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): July 15, 2004

Medicis Pharmaceutical Corporation
(Exact Name of Registrant as Specified in Charter)

Delaware 0-18443 52-1574808
(State or Other Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)

8125 North Hayden Road
Scottsdale, Arizona 85258-2463
(Address of Principal (Zip Code)
Executive Offices)

Registrant's telephone number, including area code: (602) 808-8800

N/A

(Former Name or Former Address, if Changed Since Last Report)

=====

Item 5. Other Events

On July 15, 2004, Medicis Pharmaceutical Corporation (the "Company") issued a press release announcing that it had entered into an exclusive license agreement with Q-Med AB ("Q-Med") to market, distribute, sell and commercialize in the United States and Canada Q-Med's product currently known as SubQ(TM).

A copy of the Company's press release is attached hereto as Exhibit

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

99.1.

Item 7. Financial Statements and Exhibits

(a) Financial Statements of Business Acquired.

Not Applicable.

(b) Pro Forma Financial Information.

Not Applicable.

(c) Exhibits.

99.1 Copy of press release, dated July 15, 2004, issued by Medicis
Pharmaceutical Corporation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.

MEDICIS PHARMACEUTICAL CORPORATION
(Registrant)

Date: July 15, 2004

/s/ Mark A. Prygocki, Sr.

Name: Mark A. Prygocki, Sr.
Title: Executive Vice President,
Chief Financial Officer,
Corporate Secretary and
Treasurer

EXHIBIT INDEX

EXHIBIT NUMBER -----	DESCRIPTION -----
99.1	Copy of press release, dated July 15, 2004, issued by Medicis Pharmaceutical Corporation